TriSalus Life Sciences Raises $40M via 9.76M Shares at $4.10, Option for 1.46M More
TriSalus Life Sciences priced an underwritten public offering of 9,756,100 common shares at $4.10 per share, generating approximately $40.0 million in gross proceeds. The underwriter has a 30-day option for 1,463,415 additional shares (15%) at the same price, and the offering is expected to close on February 23, 2026.
1. Offering Terms
TriSalus Life Sciences has priced the offering of 9,756,100 common shares at $4.10 per share, for gross proceeds of approximately $40.0 million before underwriting discounts, commissions and expenses.
2. Underwriter Option and Closing
Lake Street Capital Markets is sole book-runner, with a 30-day option to purchase 1,463,415 common shares (15% of the initial offering) at $4.10 per share. The offering is slated to close on February 23, 2026, subject to customary closing conditions.
3. Company Profile
TriSalus Life Sciences is an oncology-focused medical technology company developing Pressure-Enabled Drug Delivery (PEDD) devices such as TriNav Infusion Systems for liver and pancreatic tumors, and an investigational immunotherapy candidate, nelitolimod, targeting Toll-like receptor 9 in solid tumors.